Teva Pharmaceuticals Had a Very Bad Day, in a Very Bad Year
In this Market Foolery podcast segment, host Chris Hill and Motley Fool One's Bill Mann consider how much worse Teva Pharmaceutical Industries (NYSE: TEVA) looks presently, after a second quarter report that featured weak sales, low profits, a 75% dividend cut, and -- to top it off -- a guidance reduction. The key difficulty for the company is that it's carrying too much debt for its size, amid an environment where its income is shrinking -- not a tenable position. But the stock is at a 13-year low. Is it a bargain yet?
A full transcript follows the video.
Source: Fool.com
Teva Pharmaceutical Industries Ltd ADR Stock
€15.00
-1.960%
With 17 Buy predictions and not the single Sell prediction the community is currently very high on Teva Pharmaceutical Industries Ltd ADR.
With a target price of 18 € there is a slightly positive potential of 20.0% for Teva Pharmaceutical Industries Ltd ADR compared to the current price of 15.0 €.
